Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
Children's of Alabama Child Health Research Unit (CHRU), Birmingham, Alabama Children's National Medical Center - Sheikh Zayed Campus - Infectious Disease, Washington D.C., District of Columbia Emory University School of Medicine, Atlanta, Georgia University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky Louisiana State University Health Shreveport - Infectious Diseases, Shreveport, Louisiana